reason report
anoth elev expect procedur guid
rais pt
bottom line reiter op increas
estim follow anoth impress sales/ep beat
procedur growth handili top consensu
ww system placement came vs consensu light
out-performance management bump procedur outlook
vs prior think could set addt
beat rais rest year continu see multipl
avenu estim upsid -- -even higher forecast -- -a
new product cycl across system sp flex cathet robot
instrument stapler new vessel sealer begin unfold
compani drive increas penetration/ accept grow set
intern market new us gen surgeri procedur area
dcf base pt goe vs higher estim
anoth high qualiti quarter upsid across board --
system procedur margin ep came ahead
expect report revenue compar
consensu out-performance driven
system instrument accessori servic revenu
in-lin beat driven better-than-expect system revenue
versu consensu system placement
revenue also contribut beat versu consensu come
versu lpe gm line
us beat consensu adj ebita mgn
vs con demonstr y/i oper leverag lower
tax rate vs think also help ep ultim beat our/
reflect upsid vs consensu reflect y/i growth
acceler us grew y/i vs fuel continu
momentum us surgeri led hernia colorect thorac well
anoth qtr better-than-expect urolog gyn trend ou y/
procedur growth vs ahead estimate
sequenti y/i lift help part time china growth
continu moder expect capac expans depend
quota govern add new system still wait
updat management atmospher tariff certainli
help acceler process management rais guidanc vs
prior mark second increas rang far year
think rang conserv got toughest
comp year momentum driver even china momentum
compani inform leerink partner llc research
revenu mm ep ex item stock expens defer revenu amort
ep adjust stock split
medic suppli devic
dcf wgtd average cost
net debt total capit
price-to-earnings lt ep growth
pleas refer page import disclosur price chart analyst certif
slow fulli intact view new procedur
slightli midpoint updat guidanc
across geographi us system
compar our/consensu estimate meaning out-performance
come xi vs forecast ou system also beat
our/consensu out-performance come vs
forecast compani continu place higher system
oper leas well total system last two quarter
thirty-four percent system placement involv trade-in
quarter indic custom
prefer newer tech
launch us shipment begin late
remind sp isrg single-arm single-port platform robotic-
assist technolog design deep narrow access tissu
bodi initi sold stand-alon system asp
premium xi eventu integr entir gen
platform add-on xi surgeon consol believ
sp may potenti help surgeon make inroad natur orific
surgeri urolog repres initi indic sp approv
system begin ship late management plan
purs follow-on indic time broaden applic
sp platform area transor surgeri final
clinic colorect surgeri transan extraperiton
applic model system placement us
system placement total system placement
assum asp translat revenu
total
model us system respect
assum asp
pipelin initi track vessel sealer
extend first qtr us launch sureform stapler
approv launch full scale launch
help drive increas penetr thorac bariatr categori
compani also submit enhanc grasper
hernia repair flexibl cathet robot platform lung
biopsi management anticip submiss -- -work
platform revenu revenue respect
japan procedur momentum start benefit new
continu emphas adopt gradual requir
market invest nonetheless addit procedur
drove higher y/i japan procedur growth accord management
increas confid potenti sustain
procedur growth beyond -- -despit slow momentum
model updat rev/ep increas reflect upsid
sales/ep increas reflect upsid slightli
aggress system placement procedur growth assumpt
project procedur growth model ww system
placement model op-ex growth
midpoint y/i guid new sales/ep also
increas sit y/i
rate share outperform ultim believ key valu driver
place stock work intermediate-to-longer-term acceler
procedur growth new product cycl momentum continu uniqu robot
colorect bariatr thorac head neck other acceler growth procedur
adopt intern dvp da vinci prostatectomi europ japan new product cycl
 xi sp flexibl cathet robot help sustain above-averag top- bottom-lin
double-digit growth system advanc continu open increment surgery/revenu
sourc time near-to-intermedi term continu see multipl avenu
drive estim upsid new product cycl gradual unfold sp lung biopsi
compani drive increas penetration/accept grow set intern market
valuat base dcf analysi yield pt discount rate
calcul use capm model price-to-earnings basi pt translat
cash ep respect current trade ex-cash
basi incl cash ex-cash incl cash vs broader market
cap med-tech average pt impli appli adj ep less
int incom cash believ isrg premium group sustain given
help drive increas penetr still-larg under-penetrated long-term
risk valuat includ high volatil wide-trad rang stock
compani relianc singl product robot potenti chang wors hospit
capit spend environ continu debat around cost/benefit come
adopt robot procedur current project valuat could risk
gyn/uro trend slow greater degre model newer gener surgeri robot
procedur slower expect adopt forecast anticipated-to-launch
nexgen sp platform delay fail gain traction launch compani cant
achiev revenu contribut model flexibl cathet robot program
key risk includ ou growth slower anticip -- -either due delay
develop new japan procedur opportun and/or new china system tender/quota
newer robot entrant mdt/jnj beyond come onto scene
result competit trial potenti caus hospit purchas cycl elong given
robot solut evalu sg invest combat competit
develop new market lead greater opex spend -- -potenti limit near-term earn
power -- -v weve model
dollar million except ep
compani report streetaccount leerink partner llc estim
segment result ex total revenu first order analyt consensu
dollar million except ep
compani report leerink partner llc estim
compani report leerink partner llc estim
dollar million except per share data
good sold ex-amort/sbc/def cog
pre-split dilut averag share million
post-split dilut averag share million
compani report leerink partner llc estim
note adopt revenu contract custom effect januari use full retrospect method prior period tabl present financi result restat reflect effect adopt
dollar million except per share data
total
compani report leerink partner llc estim
note adopt revenu contract custom effect januari use full retrospect method prior period tabl present financi result restat reflect effect
